Neuronetics, Inc.
(STIM)
Add Watchlist
2.61 USD +0.02
Closed: 17 May, 3:55 pm
Symbol STIM
Market Cap 78.2M
Price 2.61
Open 2.54
52-wk High 5.07
50 Day Avg 3.83
Earnings Announcement 2024-08-06
Website https://www.neurostar.com
Name Neuronetics, Inc.
Shares Outstanding 29,997,600
Change % 3.5714%
Low 2.52
52-wk Low 1.03
200 Day Avg 2.52
Last Dividend 0.00
Exchange NASDAQ
Volume 207,326
Previous Close 2.52
High 2.64
EPS -0.94
PE -2.78
Avg Volume 180,775
CUSIP 64131A105
Neuronetics, Inc. Outlook
Description Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Currency USD
ISIN US64131A1051
Industry Medical - Diagnostics & Research
Changes 0.09
CUSIP 64131A105
Range 1.03 - 5.07
Beta 2.50
CIK 0001227636

Neuronetics, Inc. News

15-May-2024 7:32 AM

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents

Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older

07-May-2024 5:16 PM

Neuronetics, Inc. (STIM) Q1 2024 Earnings Call Transcript

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2024 Results Conference Call May 7, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Adam Maeder - Piper & Sandler Margaret Kaczor - William and Blair Danny Stauder - Citizens JMP Operator Thank you for standing by. Welcome to the Neuronetics First Quarter 2024 Conference Call.

07-May-2024 9:41 AM

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.38 per share a year ago.

07-May-2024 7:30 AM

Neuronetics Reports Record First Quarter 2024 Financial and Operating Results

MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024.

03-May-2024 4:30 PM

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company's common stock (RSUs) to thirteen new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company.

01-May-2024 8:31 AM

NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance

23-Apr-2024 4:30 PM

Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call

MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs . To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar is also indicated as a first-line, adjunct for MDD in adolescents 15 and older. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 6.1 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com. Investor Contact: Mike Vallie or Mark KlausnerICR [email protected] Media Contact: [email protected]

10-Apr-2024 8:31 AM

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

Lack of early symptom improvement is not predictive of final responder status Lack of early symptom improvement is not predictive of final responder status

01-Apr-2024 11:56 AM

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

27-Mar-2024 4:30 PM

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company's common stock (RSUs) to eleven new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company.

25-Mar-2024 8:30 AM

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older